Advertisement
Canada markets close in 5 hours 24 minutes
  • S&P/TSX

    21,950.90
    +65.52 (+0.30%)
     
  • S&P 500

    5,101.65
    +53.23 (+1.05%)
     
  • DOW

    38,269.98
    +184.18 (+0.48%)
     
  • CAD/USD

    0.7320
    -0.0004 (-0.05%)
     
  • CRUDE OIL

    83.70
    +0.13 (+0.16%)
     
  • Bitcoin CAD

    88,075.98
    +1,334.54 (+1.54%)
     
  • CMC Crypto 200

    1,344.84
    -51.69 (-3.70%)
     
  • GOLD FUTURES

    2,351.50
    +9.00 (+0.38%)
     
  • RUSSELL 2000

    2,001.03
    +19.91 (+1.00%)
     
  • 10-Yr Bond

    4.6490
    -0.0570 (-1.21%)
     
  • NASDAQ

    15,909.80
    +298.04 (+1.91%)
     
  • VOLATILITY

    15.26
    -0.11 (-0.72%)
     
  • FTSE

    8,138.85
    +59.99 (+0.74%)
     
  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     
  • CAD/EUR

    0.6841
    +0.0020 (+0.29%)
     

Walgreens Boots Alliance (WBA) Stock Sinks As Market Gains: What You Should Know

Walgreens Boots Alliance (WBA) closed at $30.32 in the latest trading session, marking a -0.16% move from the prior day. This move lagged the S&P 500's daily gain of 0.99%.

Heading into today, shares of the largest U.S. drugstore chain had lost 4.98% over the past month, lagging the Retail-Wholesale sector's loss of 0.04% and the S&P 500's gain of 0.42% in that time.

Wall Street will be looking for positivity from Walgreens Boots Alliance as it approaches its next earnings report date. The company is expected to report EPS of $1.10, up 14.58% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $33.84 billion, up 3.83% from the year-ago period.

WBA's full-year Zacks Consensus Estimates are calling for earnings of $4.50 per share and revenue of $136.18 billion. These results would represent year-over-year changes of -10.71% and +2.62%, respectively.

ADVERTISEMENT

Investors should also note any recent changes to analyst estimates for Walgreens Boots Alliance. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.

Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. Walgreens Boots Alliance is currently a Zacks Rank #3 (Hold).

Digging into valuation, Walgreens Boots Alliance currently has a Forward P/E ratio of 6.75. This valuation marks a no noticeable deviation compared to its industry's average Forward P/E of 6.75.

Also, we should mention that WBA has a PEG ratio of 2.23. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Retail - Pharmacies and Drug Stores industry currently had an average PEG ratio of 1.74 as of yesterday's close.

The Retail - Pharmacies and Drug Stores industry is part of the Retail-Wholesale sector. This industry currently has a Zacks Industry Rank of 221, which puts it in the bottom 13% of all 250+ industries.

The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Walgreens Boots Alliance, Inc. (WBA) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research